A leading independent European specialty pharmaceutical company
July 2, 2014
May 5, 2014
More detail available on
Norgine believes in interacting and providing financial support to patient and non-profit organisations that will ensure high quality provision of information for patients.
Norgine believes that relationships and collaborations between healthcare professionals and the pharmaceutical sector are beneficial.
Norgine will continue to execute its strategy to build upon its position as a leading independent European specialty pharmaceutical company
@Norgine's COO Peter Martin is appointed as member of #EUCOPE executive board
RT @EASLnews: #EU Commission's answer to written question on low profile of #liver diseases. Visit http://t.co/6ioW7HFZ8a
@norgine short listed for UK Prix Galien #GalienFdn Meet us at awards in Oct. 2014
RT @Gut_BMJ: Gut article in the NY Times blog! Read for more: http://t.co/uCB6Pq9yfu
Complications of cirrhosis: QoL impact on patients and their caregivers. Norgine’s symposium. 18 June. 6pm. #BSG2014
Norgine B.V., Hogehilweg 7. 1101 CA Amsterdam Zuid-Oost. The Netherlands. Registered number 30127007. Copyright Norgine 2014
All product names mentioned in this website are trademarks owned by or licensed to the Norgine group of companies, unless otherwise noted